Efficacy of live lactobacillus preparations in treating cervical inflammation and clearing viral infections in patients with HPV infection complicated by bacterial vaginosis

Yan Cui, Xiaoping Cheng

Abstract

This study aimed to evaluate the efficacy and safety of Dingjunsheng, a live Lactobacillus preparation, as adjuvant therapy in patients with human papillomavirus (HPV) infection complicated by bacterial vaginosis (BV). A retrospective analysis was conducted on 152 eligible patients, randomly divided into two groups: the observation group (n=87) receiving standard BV antibacterial therapy plus Dingjunsheng, and the control group (n=65) who received standard BV antibacterial therapy alone. The patients were followed up for six months. Primary outcomes included HPV clearance rate and cervical cytological inflammation improvement, while secondary outcomes involved BV recurrence rate and adverse reaction incidence. The results showed that the observation group had a significantly higher HPV clearance rate (73.6% vs 53.9%) and inflammation improvement rate (90.8% vs 76.9%), as well as a lower BV recurrence rate (3.1% vs 13.9%) compared to the control group. Dingjunsheng was identified as an independent protective factor for HPV clearance (OR=2.5, 95%CI:1.3–5.1). The incidence of adverse reactions was similar between both groups. We conclude that Dingjunsheng adjuvant therapy demonstrated effectiveness in improving HPV clearance, alleviating inflammation, and reducing BV recurrence, with good safety, making it a valuable treatment strategy for these patients.

Full Text:

PDF

References

Liu Y and Ai H. Comprehensive insights into human papillomavirus and cervical cancer: Pathophysiology, screening, and vaccination strategies. Biochim Biophys Acta Rev Cancer 2024; 1879:189192.

Ye Z, Zhao Y, Chen M, Lu Q, Wang J, Cui X, Wang H, Xue P and Jiang Y. Distribution and diagnostic value of single and multiple high-risk HPV infections in detection of cervical intraepithelial neoplasia: A retrospective multicenter study in China. J Med Virol 2024; 96:e29835.

Mlynarczyk-Bonikowska B, Rudnicka L. HPV Infections-Classification, Pathogenesis, and Potential New Therapies. Int J Mol Sci 2024; 25:7616.

Lin K, Hong Q, Fu Y, Tu H, Lin H, Huang J, Hu Y, Huang M and Chen M. Cervical HPV infection and related diseases among 149,559 women in Fujian: an epidemiological study from 2018 to 2023. Front Microbiol 2024; 15:1418218.

Liu Y, Li R, Liu J, Liang X, Su M, Wang S and Mu B. Exploring the role of the vaginal microbiome in HPV infection dynamics: A prospective cohort study. iScience 2025; 28:112476.

Muzny CA, Balkus J, Mitchell C, Sobel JD, Workowski K, Marrazzo J and Schwebke JR. Diagnosis and Management of Bacterial Vaginosis: Summary of Evidence Reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines. Clin Infect Dis 2022; 74:S144–S151.

Xu X, Zhang Y, Yu L, Shi X, Min M, Xiong L, Pan J, Liu P, Wu G and Gao G. A cross-sectional analysis about bacterial vaginosis, high-risk human papillomavirus infection, and cervical intraepithelial neoplasia in Chinese women. Sci Rep 2022; 12:6609.

MacLean F, Tsegaye AT, Graham JB, Swarts JL, Vick SC, Potchen NB, Cruz Talavera I, Warrier L, Dubrulle J, Schroeder LK, Saito A, Mar C, Thomas KK, Mack M, Sabo MC, Chohan BH, Ngure K, Mugo NR, Lingappa JR, Lund JM and Kinga Study Team. Bacterial vaginosis associates with dysfunctional T cells and altered soluble immune factors in the cervicovaginal tract. J Clin Invest 2025; 135:e184609.

Usyk M, Schlecht NF, Pickering S, Williams L, Sollecito CC, Gradissimo A, Porras C, Safaeian M, Pinto L, Herrero R, Strickler HD, Viswanathan S, Nucci-Sack A, Diaz A, Costa Rica HPV Vaccine Trial (CVT) Group and Burk RD. molBV reveals immune landscape of bacterial vaginosis and predicts human papillomavirus infection natural history. Nat Commun 2022; 13:233.

Liu H-M, Zhang F, Cai H-Y, Lv Y-M and Pi M-Y. Cross-Sectional Study on the Correlation Between Vaginal Microecology and High-Risk Human Papillomavirus Infection: Establishment of a Clinical Prediction Model. Int J Womens Health 2024; 16:1765–1774.

Ramírez AT, Valls J, Baena A, Rojas FD, Ramírez K, Álvarez R, Cristaldo C, Henríquez O, Moreno A, Reynaga DC, Palma HG, Robinson I, Hernández DC, Bardales R, Cardinal L, Salgado Y, Martínez S, González E, Guillén D, Fleider L, Tatti S, Villagra V, Venegas G, Cruz-Valdez A, Valencia M, Rodríguez G, Terán C, Picconi MA, Ferrera A, Kasamatsu E, Mendoza L, Calderon A, Luciani S, Broutet N, Darragh T, Almonte M, Herrero R and ESTAMPA Study Group. Performance of cervical cytology and HPV testing for primary cervical cancer screening in Latin America: an analysis within the ESTAMPA study. Lancet Reg Health Am 2023; 26:100593.

Medina-Rivero AS, Ratkovich-Gonzalez S, Ruiz-Briseño MDR and Rosas-González VC. The Role of Cervicovaginal Microbiota and Probiotics in Modulating HPV Persistence and Preventing Cervical Cancer. ACS Infect Dis 2025.

Liu P, Lu Y, Li R, Chen X. Use of probiotic lactobacilli in the treatment of vaginal infections: In vitro and in vivo investigations. Front Cell Infect Microbiol 2023; 13:1153894.

Sherrard J, Wilson J, Donders G, Mendling W and Jensen JS. 2018 European (IUSTI/WHO) International

Union against sexually transmitted infections (IUSTI) World Health Organisation (WHO) guideline on the management of vaginal discharge. Int J STD AIDS 2018; 29:1258–1272.

Xue Fengxia, Infectious Disease Collaboration Group, Obstetrics and Gynecology Branch and Chinese Medical Association. Guidelines for the Diagnosis and Treatment of Bacterial Vaginosis (Revised Edition 2021). Chinese Journal of Obstetrics and Gynecology 2021; 56:3–6. [in Chinese]

National Cancer Institute (NCI). Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0[R]. Bethesda, MD: NCI, 2017.

Solomon D, Davey D, Kurman R, Moriarty A, O’Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T, Young N, Forum Group Members and Bethesda 2001 Workshop. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002; 287:2114–2119.

Bhattacharya A, Das S, Bhattacharjee MJ, Mukherjee AK and Khan MR. Comparative pangenomic analysis of predominant human vaginal lactobacilli strains towards population-specific adaptation: understanding the role in sustaining a balanced and healthy vaginal microenvironment. BMC Genomics 2023; 24:565.

Das S, Bhattacharjee MJ, Mukherjee AK and Khan MR. Recent advances in understanding of multifaceted changes in the vaginal microenvironment: implications in vaginal health and therapeutics. Crit Rev Microbiol 2023; 49:256–282.

Swidsinski S, Moll WM and Swidsinski A. Bacterial Vaginosis-Vaginal Polymicrobial Biofilms and Dysbiosis. Dtsch Arztebl Int 2023; 120:347–354.

Plummer EL, Vodstrcil LA, Danielewski JA, Murray GL, Doyle ML, Latimer RL, Fairley CK, Chow EPF, Garland SM and Bradshaw CS. Vaginal anaerobes are associated with cervicitis: A case-control study. J Infect 2024; 89:106210.

Lyu J, Gao M, Zhao S, Liu X, Zhao X, Zou Y, Zhong Y, Ge L, Zhang H, Huang L, Fan S, Xiao L and Zhang X. From whole genomes to probiotic candidates: A study of potential lactobacilli strains selection for vaginitis treatment. Heliyon 2024; 10:e30495.

Zeng X, An R, Li H and Zhang Y. Improved treatment of vulvovaginal candidiasis with Clotrimazole plus probiotic Lacidophilin Vaginal Capsules: A prospective, real-world study. Medicine (Baltimore) 2023; 102:e32664.

Zhang R, Liu Z, Zhang Y, Mi L, Zhang D, Li Y and Liao Q. Probiotics reduce the recurrence of asymptomatic bacterial vaginosis in Chinese women. Sci Rep 2025; 15:9689.

Aranda-Rivera AK, Cruz-Gregorio A, Briones-Herrera A and Pedraza-Chaverri J. Regulation of autophagy by high- and low-risk human papillomaviruses. Rev Med Virol 2021; 31:e2169.

Lv Z, He X, Li Z, Yuan Y, Zhou X, Tu C, Yang Y, Huang Y, Yin L, Chen H and Tao Y. Outcomes and associated factors of cervical human papillomavirus infection among 608 women in Shenzhen, China, 2018-2023. Front Public Health 2024; 12:1523839.

Zhao S, Yang H, Lv A, Zhang S, Hui Y, Qi W, Zhao H, Miao M, Wang Y, Yin Y, Wang Q, Chen S and Wang X. Vaginal Microbiome and Metabolome Profiles Among HPV Positive and HPV Negative Women Based on Stratification of Vaginitis. J Med Virol 2025; 97:e70385.

Zhang Y, Xu X, Yu L, Shi X, Min M, Xiong L, Pan J, Zhang Y, Liu P, Wu G and Gao G. Vaginal Microbiota Changes Caused by HPV Infection in Chinese Women. Front Cell Infect Microbiol 2022; 12:814668.

Carmain M, Sappenfield EC and Tunitsky-Bitton E. Probiotics: utility, benefits, and risks for gynecologic conditions. Curr Opin Obstet Gynecol 2025; 37:426–431.

Xu P, Mageswary U, Nisaa AA, Balasubramaniam SD, Samsudin SB, Rusdi NIBM, Jerip ARA, Oon CE, Bakar MHA, Rajendran D, Tan JJ, Roslan FF, Sreenivasan S, Balakrishnan V, Sany SB, Tan CS and

Liong MT. Probiotic reduces vaginal HPV abundance, improves immunity and quality of life in HPV-positive women: a randomised, placebo-controlled and double-blind study. Benef Microbes 2025; 16:667–684.

Liu Y, Zhao X, Wu F, Chen J, Luo J, Wu C and Chen T. Effectiveness of vaginal probiotics Lactobacillus crispatus chen-01 in women with high-risk HPV infection: a prospective controlled pilot study. Aging (Albany NY) 2024; 16:11446–11459.

Chen R, Li R, Qing W, Zhang Y, Zhou Z, Hou Y, Shi Y, Zhou H and Chen M. Probiotics are a good choice for the treatment of bacterial vaginosis: a meta-analysis of randomized controlled trial. Reprod Health 2022; 19:137.

Refbacks

  • There are currently no refbacks.